Role of newer azoles in surgical patients

Journal of Chemotherapy

Volumn 11, Issue 6, 1999, Pages 504-512

  Patterson, Thomas F ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Antifungal agents; Azoles; Fluconazole; Fungal infection; Molds; Voriconazole; Yeasts

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; POSACONAZOLE; PYRROLE DERIVATIVE; RAVUCONAZOLE; VORICONAZOLE;

ABDOMINAL SURGERY; CANDIDA ALBICANS; CONFERENCE PAPER; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG TOLERANCE; FEVER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKOCYTOSIS; MORBIDITY; MORTALITY; MYCOSIS; NEPHROTOXICITY; NONHUMAN; SURGICAL PATIENT; VISUAL DISORDER;

EID: 0033382276     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.1999.11.6.504     Document Type: Conference Paper

References (39)

1. 1 Beck-Sague C, Jarvis WR. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System. J Infect Dis 1993; 167: 1247-51.
2. 2 Rangel-Frausto MS, Wiblin T, Blumberg H, et al. National epidemiology of mycoses survey (NEMIS): Variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units. Clin Infect Dis 1999; 29: 253-8.
3. 3 Tollemar J, Ericzon BG, Barkholt L, Andersson J, Ringden O, Groth CG. Risk factors for deep Candida infections in liver transplant recipients. Transplant Proc 1990; 22: 1826-7.
4. 4 Eggimann P, Francioli P, Bille J, et al. Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. Crit Care Med 1999; 27: 1066-72.
5. 5 Collins LA, Samore MH, Roberts MS, et al. Risk factors for invasive fungal infections complicating orthotopic liver transplantation. J Infect Dis 1994; 170: 644-52.
6. 6 Patel R, Paya CV. Infections in solid organ transplant recipients. Clin Microbiol Rev 1997; 10: 86-124.
7. 7 Patterson TF. Editorial response: Approaches to the therapy of invasive mycoses - the role of amphotericin B. Clin Infect Dis 1998; 26: 339-40.
8. 8 Patterson TF, Kirkpatrick WR, White M, et al. Therapy of invasive aspergillosis: Disease spectrum, treatment practices, and outcomes (LM38). 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans LA, 1996 (abstract).
9. 9 Coleman DC, Rinaldi MG, Haynes KA, et al. Importance of Candida species other than Candida albicans as opportunistic pathogens. Med Mycol 1998; 36 (suppl. 1): 156-165.
10. 10 Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp JE, Saral R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991; 325: 1274-7.
11. 11 Morrison VA, Haake RJ, Weisdorf DJ, Peterson BA. Non-candidal fungal infections after bone marrow transplantation. Risk factors and outcome. Am J Med 1994; 96: 497-503.
12. 12 Denning DW: Invasive aspergillosis. Clin Infect Dis 1998; 26: 781-803.
13. 13 Patterson TF. Invasive aspergillosis in organ transplantation. IM-Internal Medicine. Montvale NJ: Medical Economics, 1995: 11-4.
14. 14 Kusne S, Torre-Cisneros J, Manez R, et al. Factors associated with invasive aspergillosis and the significance of positive Aspergillus cultures after liver transplantation. J Infect Dis 1992; 166: 1379-83.
15. nd Infectious Disease Society of America, Orlando, October 1994: abstract 69.
16. 16 Horvath JA, Dummer S. The use of respiratory-tract cultures in the diagnosis of invasive pulmonary aspergillosis. Am J Med 1996; 100: 171-8.
17. 17 Vanden Bossche H, Dromer F, Improvisi I, Lozano-Chiu M, Rex JH, Sanglard D. Antifungal drug resistance in pathogenic fungi. Med Mycol 1998; 36 (suppl. 1): 119-428.
18. 18 White TC, Marr KA, Bowden RA. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev 1998; 11: 382-402.
19. 19 Revankar SG, Kirkpatrick WR, McAtee R, et al. Detection and significance of fluconazole resistance in oropharyngeal candidiasis in HIV-infected patients. J Infect Dis 1996; 174: 821-7.
20. 20 Redding S, Smith J, Farinacci G, et al. Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: Documentation by in vitro susceptibility testing and DNA subtype analysis. Clin Infect Dis 1994; 18: 240-2.
21. 21 Pfaller MA, Rhine-Chalberg J, Barry AL, Rex JH. Strain variation and antifungal susceptibility among bloodstream isolates of Candida species from 21 different medical institutions. Clin Infect Dis 1995; 21: 1507-9.
22. 22 Rex JH, Pfaller MA, Galgiani JN, et al. Development of interpretive breakpoints for antifungal susceptibility testing: Conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin Infect Dis 1997; 24: 235-47.
23. 23 Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. Hospital-acquired candidemia. The attributable mortality and excess length of stay. Arch Intern Med 1988; 148: 2642-5.
24. th Annual Meeting of the Infectious Diseases Society of America, Denver CO, November, 1998.
25. 25 Nguyen MH, Peacock JE, Jr, Morris AJ, et al. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med 1996; 100: 617-23.
26. 26 Pfaller MA, Jones RN, Messer SA, Edmond MB, Wenzel RP. National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. SCOPE Participant Group. Surveillance and Control of Pathogens of Epidemiologic. Diagn Microbiol Infect Dis 1998; 30: 121-9.
27. 27 Pfaller MA, Jones RN, Doern GV, Sader MS, Hollis RJ, Messer SA. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada, and South America for the SENTRY Program. The SENTRY Participant Group, J Clin Microbiol 1998; 36: 1886-9.
28. 28 Edwards JE Jr, Bodey GP, Bowden RA, et al. International conference for the development of a consensus on the management and prevention of severe candidal infections. Clin Infect Dis 1997; 25: 43-59.
29. 29 Revankar SG, Dib OP, Kirkpatrick WR, et al. Clinical evaluation and microbiology of oropharyngeal infection due to fluconazole-resistant Candida in human immunodeficiency virus-infected patients. Clin Infect Dis 1998; 26: 960-3.
30. 30 National Committee for Clinical and Laboratory Standards. Reference method for broth dilution antifungal susceptibility of yeasts. Approved standard M27-A. Wayne, PA: National Committee for Clinical and Laboratory Standards, 1997.
31. 31 Sheehan DJ, Hitchcock CA, Sibley CM. Current and emerging azole antifungal agents. Clin Microbiol Rev 1999; 12: 40-79.
32. 32 Pfaller MA, Messer SA, Hollis RJ, et al. In vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, Sch 56592, and voriconazole. Antimicrob Agents Chemother 1998; 42: 3242-4.
33. 33 Groll AH, Piscitelli SC, Walsh TJ. Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Adv Pharmacol 1998; 44: 343-500.
34. 34 Rex JH, Pfaller MA, Barry AL, Nelson PW, Webb CD. Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. NIAID Mycoses Study Group and the Candidemia Study Group. Antimicrob Agents Chemother 1995; 39: 40-4.
35. 35 Nguyen MH, Peacock JE Jr, Tanner DC, et al. Therapeutic approaches in patients with candidemia. Evaluation in a multicenter, prospective, observational study. Arch Intern Med 1995; 155: 2429-3.
36. 36 Anaissie EJ, Vartivarian SE, Abi-Said D, et al. Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study. Am J Med 1996; 101: 170-6.
37. th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco CA, 1995, abstract F81.
38. 38 Denning DW, Del Favero A, Gluckman E, et al. The efficacy and tolerability of UK 109,496 (voriconazole) in the treatment of invasive aspergillosis (P552). Abstracts of the 13th Int. Soc. for Human and Animal Mycology, Salsomaggiore, Italy, 1997.
39. th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco CA, 1999.